CSNK2A1 and neoplasm: Of these, CSNK2A1 and PRKCE are inversely correlated with dasatinib sensitivity (i. e., low levels of these two genes result in higher sensitivity to dasatinib) and therefore are potential secondary targets (e. g., drugs which reduce their levels or activity in tumor cells would sensitize these cells to dasatinib).